Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCM Granules for AECOPD Risk Window
NCT04851093Unknown
- Sponsor
- Henan University of Chinese Medicine
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Randomised, double-blind trial of Yiqiwenfei, Fuzhengqinghua and Fuzhengzaohua in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Henan University of Chinese Medicine. Primary endpoints: Acute exacerbation rate in the AECOPD Risk Window at 8 weeks and COPD Assessment Test (CAT) in the AECOPD Risk Window at 8 weeks. Status: unknown.
02
Drugs
YiqiwenfeiFuzhengqinghuaFuzhengzaohua
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04851093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851093.